(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:
----------
Acuity RM Group PLC - London-based provider of risk management services - Subsidiary Acuity Risk Management Ltd wins three-year contract worth GBP161,000 for the use of Acuity's software platform Stream by a new client to manage their ISO 27001 framework and "excellence of service." Acuity RM Chief Executive Officer Angus Forrest says: "It is a great pleasure to win a contract with a company where there is potential to grow the account substantially. In this case it also brings a new partner into the Acuity orbit of operations, with the potential to assist Acuity grow in global markets."
----------
Brand Architekts Group PLC - London-based challenger brand business in beauty sector - In the financial year that ended June 30, pretax loss widens to GBP6.8 million from GBP4.1 million a year prior. Revenue climbs 40% to GBP20.1 million from GBP14.3 million. Cost of sales increases 27% to GBP12.1 million from GBP9.5 million. Commercial and administrative costs increase to GBP10.2 million from GBP6.9 million. Exceptional items cost regarding impairment of intangible assets balloons to GBP3.5 million from GBP500,000. Looking ahead, company says: "The immediate priorities are driving brand awareness of key Invest and Nurture brands, delivering revenue synergies through international expansion, a laser focus on brand contribution and releasing working capital tied up in harvest brands. We remain confident that the foundations we are building will enable us to return to profitability and achieve our medium and long-term goals."
----------
Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - In the six months to September 30, pretax loss narrows to GBP1.5 million from GBP2.2 million a year prior. Revenue is GBP396,000 compared to none a year ago. Operating expenses decrease to GBP1.9 million from GBP2.2 million. Looking ahead, Evgen Pharma says: "In the last six months the company has completed an insightful...volunteer study and continues to analyse gene expression data from the study. These results will be made public when the analysis is complete. Evgen continues to work closely with its partner Stalicla on its programme in ASD and will provide updates as the programme proceeds. The company anticipates publication of the radio-sensitisation data for SFX-01 in models of rhabdomyosarcoma from collaborator La Sapienza University, Rome in early 2024."
----------
Georgia Capital PLC - Tbilisi-based investor focusing on domestic businesses in Georgia - Net asset value per share on a sterling basis improves 6.0% to GBP23.44 as at September 30 from GBP22.12 at June 30. On a Georgian lari basis, rises 5.1% to GEL76.99, from GEL73.28 during the same time period. Revenue in the first nine months of 2023 rises 9.6% to GEL1.53 billion, around GBP470.7 million, from GEL1.40 billion a year prior. Earnings before interest, tax, depreciation and amortisation improve 4.2% to GEL193.1 million from GEL185.3 million. Looking ahead, Chair and CEO Irakli Gilauri expects the company to be "extremely well-positioned to deliver consistent NAV per share growth in the medium to long term, all while making further progress on our key strategic and capital management priorities."
----------
Strip Tinning Holdings PLC - Birmingham-based electrical connectors provider for automotive sector - In the third quarter of 2023, trading was in line with own expectations. Strip Tinning expects to meet 2023 market guidance, which is revenue of GBP9.4 million, down around 8.1% from GBP10.2 million in 2022, adjusted Ebitda of GBP100,000, swung from an adjusted Ebitda loss of GBP2.3 million, and net debt of GBP3.6 million, narrowed from GBP4.2 million.
----------
Voyager Life PLC - Australia-focused mineral exploration and development company - Expects revenue in the first half of 2023 to be over GBP165,000, up from GBP135,000 a year ago. Expects gross margin of around 43% compared to 44% a year prior. Chief Executive Officer Nick Tulloch says: "October has seen two notable interventions in the CBD market, first from the Food Standards Agency and then from the UK government. As we would expect to see in any fast growing market, regulators are becoming more involved in the formulation of CBD and cannabinoid products. At first glance, the new guidance from the FSA would appear to limit the scope of the industry but, in fact, the effect on our business in the two weeks since publication appears to be positive."
----------
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
